FGP
BBIO icon

Freestone Grove Partners’s BridgeBio Pharma BBIO Stock Holding History

Freestone Grove Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$188K Buy
+2,524
New +$177K ﹤0.01% 800
2026
Q1 		– Sell
-125,201
Closed -$9.58M – 990
2025
Q4 		$9.58M Buy
125,201
+31,732
+34% +$2.08M 0.07% 296
2025
Q3 		$4.85M Buy
+93,469
New +$4.56M 0.04% 336

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Freestone Grove Partners's BBIO Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 2,524 shares worth $188K. The stake represents ﹤0.01% of the portfolio and ranks #800 among its holdings. This is a return to the name: Freestone Grove Partners previously reported a position in BBIO as recently as Q4 2025.

Freestone Grove Partners first reported a position in BBIO in Q3 2025 and has held it in 3 quarters since. The position peaked at $9.58M in Q4 2025. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Freestone Grove Partners held 2,524 shares of BridgeBio Pharma worth $188K as of Q2 2026.
  • BridgeBio Pharma was a new Freestone Grove Partners position in Q2 2026.
  • BridgeBio Pharma made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #800 holding.
  • Freestone Grove Partners first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 3 quarters since.
  • Freestone Grove Partners's BridgeBio Pharma position peaked at $9.58M in Q4 2025.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.